Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Bayer
ClinicalTrials.gov Identifier:
NCT01103323
First received: April 8, 2010
Last updated: May 28, 2015
Last verified: May 2015
Results First Received: October 19, 2012  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Condition: Metastatic Colorectal Cancer
Interventions: Drug: Regorafenib (Stivarga, BAY73-4506)
Drug: Placebo
Other: Best Supportive Care (BSC)

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Regorafenib (Stivarga, BAY73-4506)+BSC Participants received Regorafenib 160 mg per oral once daily for 3 weeks on 1 week off of every 4 week cycle plus best supportive care (BSC).
Placebo+BSC Participants received matching placebo tablets per oral once daily for 3 weeks on 1 week off of every 4 week cycle plus best supportive care (BSC). Period 1 is placebo and placebo-regorafenib with placebo period only before unblinding. Period 2 is placebo-regorafenib with regorafenib period only.

Participant Flow for 2 periods

Period 1:   Without/Before Drug Switch
    Regorafenib (Stivarga, BAY73-4506)+BSC   Placebo+BSC
STARTED   505   255 
Participants Received Treatment   500   253 
COMPLETED   429   237 
NOT COMPLETED   76   18 
Adverse Event                50                7 
Withdrawal by Subject                17                5 
Protocol Violation                2                0 
Physician Decision                2                0 
did not receive study treatment                5                2 
Switch to Regorafenib                0                4 

Period 2:   Switched From Placebo to Regorafenib
    Regorafenib (Stivarga, BAY73-4506)+BSC   Placebo+BSC
STARTED   0   4 [1] 
COMPLETED   0   3 
NOT COMPLETED   0   1 
Adverse Event                0                1 
[1] Participants in the placebo+BSC group switched to Regorafenib treatment after unblinding.



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Regorafenib (Stivarga, BAY73-4506)+BSC Participants received Regorafenib 160 mg per oral once daily for 3 weeks on 1 week off of every 4 week cycle plus best supportive care (BSC).
Placebo+BSC Participants received matching placebo tablets per oral once daily for 3 weeks on 1 week off of every 4 week cycle plus best supportive care (BSC).
Total Total of all reporting groups

Baseline Measures
   Regorafenib (Stivarga, BAY73-4506)+BSC   Placebo+BSC   Total 
Overall Participants Analyzed 
[Units: Participants]
 505   255   760 
Age [1] 
[Units: Years]
Mean (Full Range)
 60.7 
 (22 to 82) 
 60.1 
 (25 to 85) 
 60.5 
 (22 to 85) 
[1] The age of the patient in years at enrollment in the study.
Gender 
[Units: Participants]
     
Female   194   102   296 
Male   311   153   464 
Eastern Cooperative Oncology Group (ECOG) performance status (PS) before treatment [1] 
[Units: Participants]
     
 265   146   411 
 240   109   349 
[1] ECOG PS is a scale that measures how cancer affects the daily life of a patient on an ordinal scale from grade 0 (best) to grade 5 (worst). 0=Fully active without restriction; 1= Restricted in physically strenuous activity; 2= Ambulatory, capable of all selfcare; 3= Capable of limited selfcare; 4= Completely disabled; 5= Dead
KRAS mutation [1] 
[Units: Participants]
     
No   205   94   299 
Yes   273   157   430 
Unknown   27   4   31 
[1] KRAS - Kirsten rat sarcoma viral oncogene homolog (protein), member of the RAS family of GTPases (guanosine triphosphate hydrolases)


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Overall Survival   [ Time Frame: From randomization of the first subject until the database cut-off approximately 14 months later (19May2010 - 21Jul2011) used for 2nd planned formal interim analysis (IA). ]

2.  Secondary:   Progression-free Survival (Based on Investigator’s Assessment)   [ Time Frame: From randomization of the first subject until the database cut-off approximately 14 months later (19May2010 - 21Jul2011) used for 2nd planned formal interim analysis. Tumor assessed at 8 week intervals. ]

3.  Secondary:   Objective Tumor Response   [ Time Frame: From randomization of the first subject until the database cut-off approximately 14 months later (19May2010 - 21Jul2011) used for 2nd planned formal interim analysis. Tumor assessed at 8 week intervals. ]

4.  Secondary:   Disease Control   [ Time Frame: From randomization of the first subject until the database cut-off approximately 14 months later (19May2010 - 21Jul2011) used for 2nd planned formal interim analysis. Tumor assessed at 8 week intervals. ]
  Hide Outcome Measure 4

Measure Type Secondary
Measure Title Disease Control
Measure Description Disease control was defined as the percentage of patients whose best response was not PD [sum of lesion sizes increased at least 20% from smallest sum on study or new lesions] (ie, CR [tumor disappears], PR [sum of lesion sizes decreased at least 30% from baseline] or SD (stable disease)). SD included if at least 6 weeks after randomization.
Time Frame From randomization of the first subject until the database cut-off approximately 14 months later (19May2010 - 21Jul2011) used for 2nd planned formal interim analysis. Tumor assessed at 8 week intervals.  
Safety Issue No  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
ITT

Reporting Groups
  Description
Regorafenib (Stivarga, BAY73-4506)+BSC Participants received Regorafenib 160 mg per oral once daily for 3 weeks on 1 week off of every 4 week cycle plus best supportive care (BSC).
Placebo+BSC Participants received matching placebo tablets per oral once daily for 3 weeks on 1 week off of every 4 week cycle plus best supportive care (BSC)

Measured Values
   Regorafenib (Stivarga, BAY73-4506)+BSC   Placebo+BSC 
Participants Analyzed 
[Units: Participants]
 505   255 
Disease Control 
[Units: Percentage of participants]
 41.0   14.9 


Statistical Analysis 1 for Disease Control
Groups [1] All groups
Method [2] Cochran-Mantel-Haenszel
P Value [3] <0.000001
Difference [4] -25.94
95% Confidence Interval -32.06 to -19.82
[1] Additional details about the analysis, such as null hypothesis and power calculation:
  Two treatment groups compared using Cochran-Mantel-Haenszel (CMH) test adjusting for same stratification factors as at randomization.
[2] Other relevant method information, such as adjustments or degrees of freedom:
  No text entered.
[3] Additional information, such as whether or not the p-value is adjusted for multiple comparisons and the a priori threshold for statistical significance:
  Comparison based on pre-specified alpha level of 0.025 (1-sided).
[4] Other relevant estimation information:
  Difference = Placebo - Regorafenib 160 mg



5.  Secondary:   Tumor Response   [ Time Frame: From randomization of the first subject until the database cut-off approximately 14 months later (19May2010 - 21Jul2011) used for 2nd planned formal interim analysis. Tumor assessed at 8 week intervals. ]


  Serious Adverse Events
  Hide Serious Adverse Events

Time Frame AE was collected up to 30 days after end of study treatment (per protocol) over a period of approximately 3.7 years.
Additional Description Disseminated Intravascular Coagulation (DIC), International Normalized Ratio (INR), Cardiac Troponin T (cTnT), Gastroihntestina (GI), Not Otherwise Specified (NOS), Aspartate Aminotransferase (AST), Genitourinary (GU), Alanine Aminotransferase (ALT), Acute Respiratory Distress Syndrome (ARDS), Absolute Neutrophil Count (ANC)

Reporting Groups
  Description
Regorafenib (BAY73-4506)+BSC Participants received Regorafenib 160 mg per oral once daily for 3 weeks on 1 week off of every 4 week cycle plus best supportive care (BSC).
Placebo+BSC Participants received matching placebo tablets per oral once daily for 3 weeks on 1 week off of every 4 week cycle plus best supportive care (BSC). It is for placebo period only before unblinding.
Placebo - Regorafenib After Unblinding Participants in the placebo+BSC group switched to treatment with Regorafenib after unblinding. It is for Regorafenib treatment period only

Serious Adverse Events
    Regorafenib (BAY73-4506)+BSC   Placebo+BSC   Placebo - Regorafenib After Unblinding
Total, serious adverse events       
# participants affected / at risk   232/500 (46.40%)   103/253 (40.71%)   2/4 (50.00%) 
Blood and lymphatic system disorders       
DIC * 1       
# participants affected / at risk   2/500 (0.40%)   0/253 (0.00%)   0/4 (0.00%) 
# events   2   0   0 
Edema: Limb * 1       
# participants affected / at risk   1/500 (0.20%)   1/253 (0.40%)   0/4 (0.00%) 
# events   1   1   0 
Edema: Trunk/Genital * 1       
# participants affected / at risk   0/500 (0.00%)   2/253 (0.79%)   0/4 (0.00%) 
# events   0   4   0 
Edema: Viscera * 1       
# participants affected / at risk   0/500 (0.00%)   1/253 (0.40%)   0/4 (0.00%) 
# events   0   3   0 
Hemoglobin * 1       
# participants affected / at risk   4/500 (0.80%)   2/253 (0.79%)   0/4 (0.00%) 
# events   8   2   0 
INR * 1       
# participants affected / at risk   2/500 (0.40%)   0/253 (0.00%)   0/4 (0.00%) 
# events   5   0   0 
Neutrophils * 1       
# participants affected / at risk   1/500 (0.20%)   0/253 (0.00%)   0/4 (0.00%) 
# events   1   0   0 
Platelets * 1       
# participants affected / at risk   2/500 (0.40%)   0/253 (0.00%)   0/4 (0.00%) 
# events   2   0   0 
Thrombotic microangiopathy * 1       
# participants affected / at risk   1/500 (0.20%)   0/253 (0.00%)   0/4 (0.00%) 
# events   1   0   0 
Cardiac disorders       
Cardiac arrhythmia - Other * 1       
# participants affected / at risk   1/500 (0.20%)   0/253 (0.00%)   0/4 (0.00%) 
# events   1   0   0 
Cardiac ischemia/infarction * 1       
# participants affected / at risk   6/500 (1.20%)   1/253 (0.40%)   0/4 (0.00%) 
# events   6   2   0 
Hypertension * 1       
# participants affected / at risk   1/500 (0.20%)   0/253 (0.00%)   0/4 (0.00%) 
# events   1   0   0 
Hypotension * 1       
# participants affected / at risk   2/500 (0.40%)   0/253 (0.00%)   0/4 (0.00%) 
# events   2   0   0 
Left ventricular systolic dysfunction * 1       
# participants affected / at risk   1/500 (0.20%)   0/253 (0.00%)   0/4 (0.00%) 
# events   3   0   0 
Supraventricular arrhythmia, Atrial fibrillation * 1       
# participants affected / at risk   2/500 (0.40%)   0/253 (0.00%)   0/4 (0.00%) 
# events   2   0   0 
cTnT * 1       
# participants affected / at risk   1/500 (0.20%)   0/253 (0.00%)   0/4 (0.00%) 
# events   1   0   0 
Eye disorders       
Diplopia * 1       
# participants affected / at risk   1/500 (0.20%)   1/253 (0.40%)   0/4 (0.00%) 
# events   1   1   0 
Ocular - Other * 1       
# participants affected / at risk   1/500 (0.20%)   0/253 (0.00%)   0/4 (0.00%) 
# events   1   0   0 
Gastrointestinal disorders       
Anorexia * 1       
# participants affected / at risk   5/500 (1.00%)   2/253 (0.79%)   0/4 (0.00%) 
# events   8   2   0 
Ascites * 1       
# participants affected / at risk   1/500 (0.20%)   2/253 (0.79%)   1/4 (25.00%) 
# events   2   2   1 
Constipation * 1       
# participants affected / at risk   1/500 (0.20%)   0/253 (0.00%)   0/4 (0.00%) 
# events   1   0   0 
Dehydration * 1       
# participants affected / at risk   3/500 (0.60%)   2/253 (0.79%)   0/4 (0.00%) 
# events   3   2   0 
Diarrhea * 1       
# participants affected / at risk   8/500 (1.60%)   0/253 (0.00%)   0/4 (0.00%) 
# events   9   0   0 
Distension * 1       
# participants affected / at risk   1/500 (0.20%)   0/253 (0.00%)   0/4 (0.00%) 
# events   1   0   0 
Enteritis * 1       
# participants affected / at risk   1/500 (0.20%)   0/253 (0.00%)   0/4 (0.00%) 
# events   1   0   0 
Fistula, GI, Abdomen NOS * 1       
# participants affected / at risk   1/500 (0.20%)   1/253 (0.40%)   0/4 (0.00%) 
# events   2   1   0 
Fistula, GI, Anus * 1       
# participants affected / at risk   1/500 (0.20%)   0/253 (0.00%)   0/4 (0.00%) 
# events   1   0   0 
Fistula, GI, Small bowel NOS * 1       
# participants affected / at risk   1/500 (0.20%)   0/253 (0.00%)   0/4 (0.00%) 
# events   1   0   0 
GI - Other * 1       
# participants affected / at risk   1/500 (0.20%)   1/253 (0.40%)   0/4 (0.00%) 
# events   1   1   0 
Hemorrhoids * 1       
# participants affected / at risk   1/500 (0.20%)   0/253 (0.00%)   0/4 (0.00%) 
# events   1   0   0 
Ileus * 1       
# participants affected / at risk   2/500 (0.40%)   3/253 (1.19%)   0/4 (0.00%) 
# events   3   3   0 
Mucositis (functional/symptomatic), Small bowel * 1       
# participants affected / at risk   1/500 (0.20%)   0/253 (0.00%)   0/4 (0.00%) 
# events   1   0   0 
Necrosis, GI, Peritoneal cavity * 1       
# participants affected / at risk   1/500 (0.20%)   0/253 (0.00%)   0/4 (0.00%) 
# events   1   0   0 
Obstruction, GI, Colon * 1       
# participants affected / at risk   9/500 (1.80%)   6/253 (2.37%)   0/4 (0.00%) 
# events   11   8   0 
Obstruction, GI, Ileum * 1       
# participants affected / at risk   0/500 (0.00%)   1/253 (0.40%)   0/4 (0.00%) 
# events   0   1   0 
Obstruction, GI, Small bowel NOS * 1       
# participants affected / at risk   4/500 (0.80%)   7/253 (2.77%)   0/4 (0.00%) 
# events   5   9   0 
Obstruction, GI, Stomach * 1       
# participants affected / at risk   1/500 (0.20%)   0/253 (0.00%)   0/4 (0.00%) 
# events   1   0   0 
Perforation, GI, Colon * 1       
# participants affected / at risk   0/500 (0.00%)   1/253 (0.40%)   0/4 (0.00%) 
# events   0   1   0 
Stricture, GI, Biliary tree * 1       
# participants affected / at risk   1/500 (0.20%)   0/253 (0.00%)   0/4 (0.00%) 
# events   2   0   0 
Ulcer, GI, Duodenum * 1       
# participants affected / at risk   1/500 (0.20%)   0/253 (0.00%)   0/4 (0.00%) 
# events   2   0   0 
Vomiting * 1       
# participants affected / at risk   3/500 (0.60%)   0/253 (0.00%)   1/4 (25.00%) 
# events   3   0   1 
General disorders       
Constitutional symptoms - Other * 1       
# participants affected / at risk   34/500 (6.80%)   23/253 (9.09%)   0/4 (0.00%) 
# events   49   39   0 
Death not associated with CTCAE term, Disease progression NOS * 1       
# participants affected / at risk   16/500 (3.20%)   6/253 (2.37%)   1/4 (25.00%) 
# events   17   6   1 
Death not associated with CTCAE term, Multi-Organ Failure * 1       
# participants affected / at risk   4/500 (0.80%)   1/253 (0.40%)   0/4 (0.00%) 
# events   4   1   0 
Death not associated with CTCAE term, Sudden death * 1       
# participants affected / at risk   2/500 (0.40%)   2/253 (0.79%)   0/4 (0.00%) 
# events   2   2   0 
Fatigue * 1       
# participants affected / at risk   5/500 (1.00%)   5/253 (1.98%)   0/4 (0.00%) 
# events   6   5   0 
Fever * 1       
# participants affected / at risk   17/500 (3.40%)   2/253 (0.79%)   0/4 (0.00%) 
# events   21   2   0 
Pain, Abdomen NOS * 1       
# participants affected / at risk   13/500 (2.60%)   2/253 (0.79%)   0/4 (0.00%) 
# events   21   2   0 
Pain, Back * 1       
# participants affected / at risk   4/500 (0.80%)   4/253 (1.58%)   0/4 (0.00%) 
# events   6   5   0 
Pain, Buttock * 1       
# participants affected / at risk   2/500 (0.40%)   0/253 (0.00%)   0/4 (0.00%) 
# events   4   0   0 
Pain, Cardiac/Heart * 1       
# participants affected / at risk   0/500 (0.00%)   1/253 (0.40%)   0/4 (0.00%) 
# events   0   1   0 
Pain, Chest wall * 1       
# participants affected / at risk   1/500 (0.20%)   0/253 (0.00%)   0/4 (0.00%) 
# events   1   0   0 
Pain, Chest/Thorax NOS * 1       
# participants affected / at risk   4/500 (0.80%)   1/253 (0.40%)   0/4 (0.00%) 
# events   4   1   0 
Pain, Extremity - limb * 1       
# participants affected / at risk   2/500 (0.40%)   0/253 (0.00%)   0/4 (0.00%) 
# events   6   0   0 
Pain, Head/Headache * 1       
# participants affected / at risk   2/500 (0.40%)   1/253 (0.40%)   0/4 (0.00%) 
# events   2   1   0 
Pain, Joint * 1       
# participants affected / at risk   1/500 (0.20%)   0/253 (0.00%)   0/4 (0.00%) 
# events   1   0   0 
Pain, Liver * 1       
# participants affected / at risk   1/500 (0.20%)   0/253 (0.00%)   0/4 (0.00%) 
# events   2   0   0 
Pain, Neuralgia/Peripheral nerve * 1       
# participants affected / at risk   0/500 (0.00%)   1/253 (0.40%)   0/4 (0.00%) 
# events   0   1   0 
Pain, Pain NOS * 1       
# participants affected / at risk   1/500 (0.20%)   0/253 (0.00%)   0/4 (0.00%) 
# events   1   0   0 
Pain, Tumor pain * 1       
# participants affected / at risk   3/500 (0.60%)   1/253 (0.40%)   0/4 (0.00%) 
# events   3   1   0 
Syndromes - Other * 1       
# participants affected / at risk   1/500 (0.20%)   0/253 (0.00%)   0/4 (0.00%) 
# events   1   0   0 
Tumor flare * 1       
# participants affected / at risk   1/500 (0.20%)   0/253 (0.00%)   0/4 (0.00%) 
# events   2   0   0 
Weight loss * 1       
# participants affected / at risk   0/500 (0.00%)   1/253 (0.40%)   0/4 (0.00%) 
# events   0   1   0 
Hepatobiliary disorders       
Cholecystitis * 1       
# participants affected / at risk   2/500 (0.40%)   0/253 (0.00%)   0/4 (0.00%) 
# events   2   0   0 
Hepatobiliary - Other * 1       
# participants affected / at risk   2/500 (0.40%)   1/253 (0.40%)   0/4 (0.00%) 
# events   2   1   0 
Liver dysfunction * 1       
# participants affected / at risk   17/500 (3.40%)   5/253 (1.98%)   0/4 (0.00%) 
# events   28   11   0 
Immune system disorders       
Allergic reaction * 1       
# participants affected / at risk   2/500 (0.40%)   0/253 (0.00%)   0/4 (0.00%) 
# events   4   0   0 
Infections and infestations       
Infection (documented clinically), Abdomen NOS * 1       
# participants affected / at risk   4/500 (0.80%)   0/253 (0.00%)   0/4 (0.00%) 
# events   4   0   0 
Infection (documented clinically), Anal/perianal * 1       
# participants affected / at risk   1/500 (0.20%)   0/253 (0.00%)   0/4 (0.00%) 
# events   1   0   0 
Infection (documented clinically), Appendix * 1       
# participants affected / at risk   1/500 (0.20%)   0/253 (0.00%)   0/4 (0.00%) 
# events   1   0   0 
Infection (documented clinically), Bladder (urinary) * 1       
# participants affected / at risk   2/500 (0.40%)   1/253 (0.40%)   0/4 (0.00%) 
# events   2   1   0 
Infection (documented clinically), Blood * 1       
# participants affected / at risk   3/500 (0.60%)   2/253 (0.79%)   0/4 (0.00%) 
# events   5   2   0 
Infection (documented clinically), Bronchus * 1       
# participants affected / at risk   3/500 (0.60%)   0/253 (0.00%)   0/4 (0.00%) 
# events   3   0   0 
Infection (documented clinically), Catheter-related * 1       
# participants affected / at risk   1/500 (0.20%)   0/253 (0.00%)   0/4 (0.00%) 
# events   2   0   0 
Infection (documented clinically), Kidney * 1       
# participants affected / at risk   1/500 (0.20%)   1/253 (0.40%)   0/4 (0.00%) 
# events   1   1   0 
Infection (documented clinically), Lung (Pneumonia) * 1       
# participants affected / at risk   9/500 (1.80%)   3/253 (1.19%)   0/4 (0.00%) 
# events   11   4   0 
Infection (documented clinically), Skin (Cellulitis) * 1       
# participants affected / at risk   1/500 (0.20%)   0/253 (0.00%)   0/4 (0.00%) 
# events   1   0   0 
Infection (documented clinically), Soft tissue NOS * 1       
# participants affected / at risk   1/500 (0.20%)   0/253 (0.00%)   0/4 (0.00%) 
# events   1   0   0 
Infection (documented clinically), Urinary tract NOS * 1       
# participants affected / at risk   2/500 (0.40%)   0/253 (0.00%)   0/4 (0.00%) 
# events   2   0   0 
Infection (documented clinically), Wound * 1       
# participants affected / at risk   1/500 (0.20%)   0/253 (0.00%)   0/4 (0.00%) 
# events   1   0   0 
Infection - Other * 1       
# participants affected / at risk   5/500 (1.00%)   1/253 (0.40%)   0/4 (0.00%) 
# events   6   2   0 
Infection with normal ANC, Blood * 1       
# participants affected / at risk   0/500 (0.00%)   1/253 (0.40%)   0/4 (0.00%) 
# events   0   1   0 
Infection with normal ANC, Catheter-related * 1       
# participants affected / at risk   1/500 (0.20%)   0/253 (0.00%)   0/4 (0.00%) 
# events   1   0   0 
Infection with normal ANC, Colon * 1       
# participants affected / at risk   1/500 (0.20%)   0/253 (0.00%)   0/4 (0.00%) 
# events   1   0   0 
Infection with normal ANC, Gallbladder (Cholecystitis) * 1       
# participants affected / at risk   1/500 (0.20%)   0/253 (0.00%)   0/4 (0.00%) 
# events   1   0   0 
Infection with normal ANC, Kidney * 1       
# participants affected / at risk   1/500 (0.20%)   0/253 (0.00%)   0/4 (0.00%) 
# events   1   0   0 
Infection with normal ANC, Lung (Pneumonia) * 1       
# participants affected / at risk   1/500 (0.20%)   1/253 (0.40%)   0/4 (0.00%) 
# events   1   1   0 
Infection with normal ANC, Soft tissue NOS * 1       
# participants affected / at risk   2/500 (0.40%)   0/253 (0.00%)   0/4 (0.00%) 
# events   2   0   0 
Infection with unknown ANC, Kidney * 1       
# participants affected / at risk   1/500 (0.20%)   0/253 (0.00%)   0/4 (0.00%) 
# events   1   0   0 
Infection with unknown ANC, Lung (Pneumonia) * 1       
# participants affected / at risk   1/500 (0.20%)   1/253 (0.40%)   0/4 (0.00%) 
# events   1   1   0 
Metabolism and nutrition disorders       
AST * 1       
# participants affected / at risk   0/500 (0.00%)   1/253 (0.40%)   0/4 (0.00%) 
# events   0   1   0 
Bilirubin (Hyperbilirubinemia) * 1       
# participants affected / at risk   8/500 (1.60%)   3/253 (1.19%)   0/4 (0.00%) 
# events   11   3   0 
Hypoalbuminemia * 1       
# participants affected / at risk   1/500 (0.20%)   0/253 (0.00%)   0/4 (0.00%) 
# events   1   0   0 
Hypocalcemia * 1       
# participants affected / at risk   1/500 (0.20%)   0/253 (0.00%)   0/4 (0.00%) 
# events   2   0   0 
Hyponatremia * 1       
# participants affected / at risk   1/500 (0.20%)   0/253 (0.00%)   0/4 (0.00%) 
# events   1   0   0 
Metabolic/Lab - Other * 1       
# participants affected / at risk   1/500 (0.20%)   0/253 (0.00%)   0/4 (0.00%) 
# events   1   0   0 
Musculoskeletal and connective tissue disorders       
Fracture * 1       
# participants affected / at risk   4/500 (0.80%)   2/253 (0.79%)   0/4 (0.00%) 
# events   4   3   0 
Gait/Walking * 1       
# participants affected / at risk   1/500 (0.20%)   0/253 (0.00%)   0/4 (0.00%) 
# events   2   0   0 
Muscle weakness left-sided * 1       
# participants affected / at risk   0/500 (0.00%)   1/253 (0.40%)   0/4 (0.00%) 
# events   0   1   0 
Muscle weakness, Extremity - lower * 1       
# participants affected / at risk   2/500 (0.40%)   0/253 (0.00%)   0/4 (0.00%) 
# events   2   0   0 
Muscle weakness, Whole body/generalized * 1       
# participants affected / at risk   0/500 (0.00%)   1/253 (0.40%)   0/4 (0.00%) 
# events   0   1   0 
Musculoskeletal - Other * 1       
# participants affected / at risk   1/500 (0.20%)   0/253 (0.00%)   0/4 (0.00%) 
# events   2   0   0 
Myositis * 1       
# participants affected / at risk   1/500 (0.20%)   0/253 (0.00%)   0/4 (0.00%) 
# events   1   0   0 
Neoplasms benign, malignant and unspecified (incl cysts and polyps)       
Secondary malignancy (possibly related to cancer treatment) * 1       
# participants affected / at risk   1/500 (0.20%)   0/253 (0.00%)   0/4 (0.00%) 
# events   2   0   0 
Nervous system disorders       
Ataxia * 1       
# participants affected / at risk   1/500 (0.20%)   0/253 (0.00%)   0/4 (0.00%) 
# events   1   0   0 
CNS ischemia * 1       
# participants affected / at risk   1/500 (0.20%)   2/253 (0.79%)   0/4 (0.00%) 
# events   2   2   0 
Cognitive disturbance * 1       
# participants affected / at risk   1/500 (0.20%)   0/253 (0.00%)   0/4 (0.00%) 
# events   1   0   0 
Confusion * 1       
# participants affected / at risk   2/500 (0.40%)   0/253 (0.00%)   0/4 (0.00%) 
# events   2   0   0 
Dizziness * 1       
# participants affected / at risk   2/500 (0.40%)   0/253 (0.00%)   0/4 (0.00%) 
# events   2   0   0 
Encephalopathy * 1       
# participants affected / at risk   1/500 (0.20%)   0/253 (0.00%)   0/4 (0.00%) 
# events   2   0   0 
Mood Alteration, Anxiety * 1       
# participants affected / at risk   1/500 (0.20%)   0/253 (0.00%)   0/4 (0.00%) 
# events   2   0   0 
Neurology - Other * 1       
# participants affected / at risk   3/500 (0.60%)   2/253 (0.79%)   0/4 (0.00%) 
# events   4   2   0 
Neuropathy: Cranial, CN III Pupil, upper eyelid, extra ocular mov * 1       
# participants affected / at risk   0/500 (0.00%)   1/253 (0.40%)   0/4 (0.00%) 
# events   0   1   0 
Neuropathy: motor * 1       
# participants affected / at risk   3/500 (0.60%)   0/253 (0.00%)   0/4 (0.00%) 
# events   3   0   0 
Seizure * 1       
# participants affected / at risk   0/500 (0.00%)   1/253 (0.40%)   0/4 (0.00%) 
# events   0   1   0 
Somnolence * 1       
# participants affected / at risk   1/500 (0.20%)   0/253 (0.00%)   0/4 (0.00%) 
# events   1   0   0 
Speech impairment * 1       
# participants affected / at risk   1/500 (0.20%)   0/253 (0.00%)   0/4 (0.00%) 
# events   1   0   0 
Syncope (Fainting) * 1       
# participants affected / at risk   2/500 (0.40%)   0/253 (0.00%)   0/4 (0.00%) 
# events   2   0   0 
Renal and urinary disorders       
Cystitis * 1       
# participants affected / at risk   2/500 (0.40%)   0/253 (0.00%)   0/4 (0.00%) 
# events   2   0   0 
Fistula, GU, Bladder * 1       
# participants affected / at risk   1/500 (0.20%)   0/253 (0.00%)   0/4 (0.00%) 
# events   1   0   0 
Obstruction, GU, Ureter * 1       
# participants affected / at risk   2/500 (0.40%)   1/253 (0.40%)   0/4 (0.00%) 
# events   2   1   0 
Renal - Other * 1       
# participants affected / at risk   0/500 (0.00%)   1/253 (0.40%)   0/4 (0.00%) 
# events   0   1   0 
Renal failure * 1       
# participants affected / at risk   5/500 (1.00%)   3/253 (1.19%)   0/4 (0.00%) 
# events   6   5   0 
Urinary retention * 1       
# participants affected / at risk   0/500 (0.00%)   2/253 (0.79%)   0/4 (0.00%) 
# events   0   2   0 
Respiratory, thoracic and mediastinal disorders       
ARDS * 1       
# participants affected / at risk   1/500 (0.20%)   1/253 (0.40%)   0/4 (0.00%) 
# events   1   1   0 
Cough * 1       
# participants affected / at risk   1/500 (0.20%)   0/253 (0.00%)   0/4 (0.00%) 
# events   2   0   0 
Dyspnea (Shortness of breath) * 1       
# participants affected / at risk   12/500 (2.40%)   4/253 (1.58%)   0/4 (0.00%) 
# events   18   4   0 
Pleural effusion * 1       
# participants affected / at risk   1/500 (0.20%)   4/253 (1.58%)   0/4 (0.00%) 
# events   2   4   0 
Pneumonitis * 1       
# participants affected / at risk   1/500 (0.20%)   1/253 (0.40%)   0/4 (0.00%) 
# events   2   1   0 
Pneumothorax * 1       
# participants affected / at risk   2/500 (0.40%)   0/253 (0.00%)   0/4 (0.00%) 
# events   3   0   0 
Pulmonary - Other * 1       
# participants affected / at risk   1/500 (0.20%)   0/253 (0.00%)   0/4 (0.00%) 
# events   1   0   0 
Skin and subcutaneous tissue disorders       
Dermatology - Other * 1       
# participants affected / at risk   1/500 (0.20%)   2/253 (0.79%)   0/4 (0.00%) 
# events   2   3   0 
Erythema multiforme * 1       
# participants affected / at risk   2/500 (0.40%)   0/253 (0.00%)   0/4 (0.00%) 
# events   2   0   0 
Hand-foot skin reaction * 1       
# participants affected / at risk   1/500 (0.20%)   0/253 (0.00%)   0/4 (0.00%) 
# events   3   0   0 
Rash/Desquamation * 1       
# participants affected / at risk   4/500 (0.80%)   1/253 (0.40%)   0/4 (0.00%) 
# events   7   1   0 
Wound complication, non-infectious * 1       
# participants affected / at risk   0/500 (0.00%)   1/253 (0.40%)   0/4 (0.00%) 
# events   0   1   0 
Vascular disorders       
Hematoma * 1       
# participants affected / at risk   0/500 (0.00%)   1/253 (0.40%)   0/4 (0.00%) 
# events   0   1   0 
Hemorrhage - Other * 1       
# participants affected / at risk   1/500 (0.20%)   0/253 (0.00%)   0/4 (0.00%) 
# events   1   0   0 
Hemorrhage pulmonary, Bronchus * 1       
# participants affected / at risk   1/500 (0.20%)   0/253 (0.00%)   0/4 (0.00%) 
# events   2   0   0 
Hemorrhage pulmonary, Mediastinum * 1       
# participants affected / at risk   1/500 (0.20%)   0/253 (0.00%)   0/4 (0.00%) 
# events   1   0   0 
Hemorrhage, GI, Abdomen NOS * 1       
# participants affected / at risk   2/500 (0.40%)   0/253 (0.00%)   0/4 (0.00%) 
# events   4   0   0 
Hemorrhage, GI, Anus * 1       
# participants affected / at risk   1/500 (0.20%)   0/253 (0.00%)   0/4 (0.00%) 
# events   2   0   0 
Hemorrhage, GI, Lower GI NOS * 1       
# participants affected / at risk   1/500 (0.20%)   0/253 (0.00%)   0/4 (0.00%) 
# events   1   0   0 
Hemorrhage, GI, Rectum * 1       
# participants affected / at risk   1/500 (0.20%)   0/253 (0.00%)   0/4 (0.00%) 
# events   1   0   0 
Hemorrhage, GI, Stoma * 1       
# participants affected / at risk   1/500 (0.20%)   0/253 (0.00%)   0/4 (0.00%) 
# events   1   0   0 
Hemorrhage, GI, Upper GI NOS * 1       
# participants affected / at risk   1/500 (0.20%)   0/253 (0.00%)   0/4 (0.00%) 
# events   1   0   0 
Hemorrhage, GI, Varices (esophageal) * 1       
# participants affected / at risk   0/500 (0.00%)   1/253 (0.40%)   0/4 (0.00%) 
# events   0   1   0 
Hemorrhage, GI, Varices (rectal) * 1       
# participants affected / at risk   1/500 (0.20%)   0/253 (0.00%)   0/4 (0.00%) 
# events   1   0   0 
Hemorrhage, GU, Vagina * 1       
# participants affected / at risk   1/500 (0.20%)   0/253 (0.00%)   0/4 (0.00%) 
# events   2   0   0 
Thrombosis/Embolism (vascular access) * 1       
# participants affected / at risk   0/500 (0.00%)   1/253 (0.40%)   0/4 (0.00%) 
# events   0   1   0 
Thrombosis/Thrombus/Embolism * 1       
# participants affected / at risk   6/500 (1.20%)   3/253 (1.19%)   0/4 (0.00%) 
# events   6   5   0 
Vascular - Other * 1       
# participants affected / at risk   1/500 (0.20%)   0/253 (0.00%)   0/4 (0.00%) 
# events   2   0   0 
* Events were collected by non-systematic assessment
1 Term from vocabulary, NCI-CTCAE v.3.0




  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
At 2nd IA, pre-specified O’Brien-Fleming-type efficacy boundary was crossed. DMC concluded OS result positive and after positive risk benefit assessment, recommended unblinding of study. OS from 2nd IA are the final formal and definitive results.


  More Information